Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research
13 Jan

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based products, and oil and gas production among other industries.

The last year has been one fraught with risks, critical elections around the globe and multiple ongoing military conflicts among other material events. Despite this, index performance as measured by the S&P was positive in 2024, with large caps outperforming mid-caps and mid-caps surpassing small caps. Much of the strong performance was driven by tech stocks and the Magnificent Seven while other areas lagged.

However, at Zacks SCR, we see a lot of opportunity in the smaller cap names. As we look forward to 2025, Zacks Chief Equity Strategist John Blank expects industrials and technology to continue their run and is recommending names in the transportation, insurance and utilities spaces. We list some of our best ideas in smaller end of the equity universe below:

  • Ligand Pharmaceuticals (NASDAQ:LGND) is a royalty aggregator which has a large opportunity set of biopharma names where it can deploy its capital for future growth.

  • MetaVia Inc. (NASDAQ:MTVA; previously NRBO) has two development assets in the metabolic space which could ride the tidal wave in the obesity driven by GLP-1 agonist success.

  • Telomir Pharmaceuticals (NASDAQ:TELO) represents another area of interest in longevity. It is developing a technology to address a variety of aging related disease.

  • In the natural resources industry, Goliath Resources (OTC:GOTRF) boasts an attractive land position and a large portfolio of future projects in gold and other metals extraction.

  • Clip Money (OTC:CLPMF), a fast-growing startup that provides inexpensive and convenient cash management services to small businesses.

  • Transportation is another attractive area represented by Titan International (NYSE:TWI). It is a global vehicle equipment manufacturer that targets the agriculture and construction markets manufacturing OEM-spec replacement products.

  • Another transportation derivative is Consumer Portfolio Services (NASDAQ:CPSS), which purchases and services auto loans. Its use of technology builds upon an improving backdrop of origination volumes.

  • For those looking to take advantage of China’s continued modernization and expanding middle class, Viomi Technology (NASDAQ:VIOT) offers home water purification in a region increasingly demanding higher water safety.

Zacks SCR offers a number of compelling ideas that may be appropriate for your portfolio in 2025. From health care to manufacturing and consumer to technology, we have several small cap ideas that leverage the most important investment themes of the coming year. View the full list of Zacks SCR’s initiation reports by analyst below.

Zacks SCR Analysts | Research Reports

Analyst

Company

Initiation Report

Description

Adaptimmune Therapeutics

ADAP

Cell therapy for cancer

Beneficient

BENF

Investment liquidity solutions

Consumer Portfolio Services

CPSS

Auto finance

Michael Kim

DeFi Technologies

DEFTF

Crypto asset management/trading

Lobo EV Technologies

LOBO

China EV: bike, scooter, golf cart

QuantaSing Group Limited

QSG

Senior products/services

ATRenew

RERE

Pre-owned consumer electronics platform

reAlpha Tech Corp.

AIRE

Real estate pricing technology

American Shared Hospital Services

AMS

Surgery equipment - gamma knife

M. Marin

SBC Medical Group Holdings

SBC

Med practice management services - cosmetics

Swiss Water Decaffeinated Coffee

SWSSF

Decaffeination of green coffee

Syra Health Corp.

SYRA

Behavioral & mental health

Azitra

AZTR

Rare skin disease

Cingulate

CING

New ADHD formulation

Grace Therapeutics

GRCE

New nimodipine formulation

John D. Vandermosten, CFA

IN8bio

INAB

Cell therapy in cancer

Ligand Pharmaceuticals

LGND

Pharma royalty aggregator

Lantheus Holdings

LNTH

Radiopharmaceuticals

Spectral AI

MDAI

Burn diagnostic

Rani Therapeutics

RANI

Oral delivery of biologics

Clip Money

CLPMF

Cash management services

Lisa Thompson

KULR Technology Group

KULR

EV battery & thermal runaway for space & aviation

Perfect Corp.

PERF

AI-based AR try-on for fashion & beauty brands

Cadrenal Therapeutics

CVKD

Anticoagulant for heart attack/stroke

David Bautz, Ph.D.

FibroBiologics

FBLG

Cell therapy, regen medicine

MetaVia (formerly NeuroBo Pharmaceuticals)

MTVA/NRBO

Cardiometabolic disease, obesity

Evaxion Biotech A/S

EVAX

DNA based cancer therapy

Brad Sorensen, CFA

NurExone Biologic

NRXBF

Paralysis reversal

Telomir Pharmaceuticals

TELO

Age reversal sciences

Ronald Wortel

Goliath Resources

GOTRF

Metals & mining

Monogram Orthopedics

MGRM

Orthopedic implants

SunCar Technology Group

SDA

Insurance & auto services in China

Thomas Kerr, CFA

Sacks Parente Golf

SPGC

Golf products

Titan International

TWI

Machinery vehicle parts

U.S. Energy Corp.

USEG

Oil & gas production

Brian Lantier, CFA

SaverOne 2014 Ltd.

SVRE

Tech for driver safety

Viomi Technology Co.

VIOT

Water filtration technology

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10